SCHEMBL6360985

SCHEMBL6360985

O=C(Cc1ccccc1)NCc1c(F)cccc1Cl

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 3/20 0.60
HTT P42858 2/20 0.57
ALDH1A1 P00352 5/20 0.56
RAB9A P51151 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.54
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52
HPGD P15428 1/20 0.52
SRC P12931 1/20 0.51
LMNA P02545 2/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
HSD17B2 P37059 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ATM Q13315 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3460926 0.79 LMNA (0.64) P2RX7HTTRAB9ASMN1; SMN2LMNA
SCHEMBL2997305 0.79 P2RX7 (0.55) P2RX7HTTALDH1A1SMN1; SMN2KMT2A
SCHEMBL19425617 0.78 P2RX7 (0.54) P2RX7HTTALDH1A1SMN1; SMN2KMT2A
SCHEMBL13167361 0.77 CYP1A2 (0.60) P2RX7HTTALDH1A1SMN1; SMN2KMT2A
SCHEMBL6357738 0.77 ATM (0.56) P2RX7HTTALDH1A1RAB9AKMT2A
SCHEMBL6357149 0.76 ATM (0.59) P2RX7HTTALDH1A1SMN1; SMN2HPGD
SCHEMBL1195120 0.76 P2RX7 (1.00) P2RX7
SCHEMBL6362545 0.75 ALDH1A1 (0.69) ALDH1A1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL12852355 0.75 CNR2 (0.67) P2RX7ALDH1A1RAB9AKMT2AMEN1
SCHEMBL3404275 0.75 P2RX7 (1.00) P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 P2RX7 448/4885HTT 761/4885ALDH1A1 1194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.